HPV Vaccine Could Protect More People With Fewer Doses, Doctors Insist

Source: www.npr.org Date: March 29, 2017 Author: Michelle Andrews You'd think that a vaccine that protects people against more than a half dozen types of cancer would have patients lining up to get it. But the human papillomavirus (HPV) vaccine, which can prevent roughly 90 percent of all cervical cancers as well as other cancers and sexually transmitted infections caused by the virus, has faced an uphill climb since its introduction more than a decade ago. Now, with a dosing schedule that requires fewer shots of a more effective vaccine, a leading oncology group has joined other clinicians and public health advocates who are pushing hard to prevent these virus-related cancers. Last year, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended reducing the number of HPV vaccine shots from three to two for girls and boys between the ages of 9 and 14. This month, the American Society of Clinical Oncologists also urged physicians in the U.S. and abroad to use the vaccine to help provide protection against cervical cancer. The CDC recommendation was based, in part, on clinical trial data that showed two doses were just as effective as a three-dose regimen for this age group. (Young people older than 14 still require three shots.) The clinical trial was conducted using Gardasil 9, a version of the vaccine approved by the Food and Drug Administration in late 2014. It protects against nine types of HPV, seven that are responsible for 90 percent of cervical [...]

2017-03-29T09:16:53-07:00March, 2017|Oral Cancer News|

Immunotherapy Making Its Mark on Head and Neck Cancer

Author: Lisa Miller Published online: 03/22/2017 Source: http://www.targetedonc.com/ Following the approval of 2 immunotherapy agents, pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of patients with head and neck cancer (HNC) over the last 6 months, immunotherapy is making its mark on the treatment paradigm for HNC. Due to the responses seen with these 2 agents, immunotherapies are being investigated further in the treatment of HNC. “Immunotherapy is a very potent treatment for some patients. In a way it shows you that we’re probably just scratching the surface with [immunotherapy treatment for HNC],” Tanguy Seiwert, MD, said during a presentation at the 1st Annual International Congress on Immunotherapies in CancerTM, hosted by the Physicians' Education Resource (PER). Findings from the KEYNOTE-012 trial led to the approval of pembrolizumab in patients with recurrent head and neck squamous cell carcinoma (HNSCC). The overall response rate was 18% with only 1 patient experiencing a complete response.1 However, about 50% of patients, both HPV-positive and HPV-negative, experienced a decrease in their target lesions. “I would like to point out that response is a terrible, terrible outcome measure for immunotherapy. In the end, what we really care about with immunotherapy is overall survival [OS],” commented Seiwert, associate program director of the Head and Neck Cancer Program, and assistant professor of medicine, The University of Chicago Medicine. “Many patients have prolonged stable disease and that likely contributes signicantly to the strong OS signal that we oftentimes see.” The phase III CheckMate 141 trial, which Seiwert said [...]

2017-03-27T09:42:03-07:00March, 2017|Oral Cancer News|

UK cancer patient receives new jaw thanks to 3D printing

Source: http://www.3ders.org/ Author: staff 3D printing techniques are being adopted with increasing regularity in surgery of all kinds, and more and more patients are seeing a hugely improved quality of life thanks to the unique benefits of the technology. The most recent success story took place in the UK, where a patient’s jawbone was entirely reconstructed using bone from his leg. The pioneering surgical procedure made use of 3D printing at various different stages. Stephen Waterhouse was diagnosed with throat cancer eight years ago, and underwent chemotherapy and radiotherapy in order to fight it. The treatments were a great success and his cancer went away, but they had an unfortunate side effect. His jawbone had started to crumble, and emergency surgery was required before it completely disintegrated. The 53-year-old was taken to Royal Stoke University Hospital, which had purchased a new 3D printer just two years previously. Costing the hospital trust around £150,000 (about $188K), the machine is the only one of its kind in the country, and was a crucial part of the effort to save the patient’s jawbone. A 3D model was designed from a scan of his remaining intact jaw and printed out as a mold, which was then used to reconstruct the jaw using bone taken from his fibula. The operation lasted around 12 hours and was a great success. According to Daya Gahir, consultant in maxillofacial and head and neck surgery, the hospital does "at least 40 major head and neck reconstructions per year. Around [...]

Magnolia man joins exclusive trial in battle against cancer

Source: www.cantonrep.com Author: Denise Sautters Rich Bartlett is looking forward to getting back to his hobbies — woodworking and nature watching — and enjoying a good steak and potato dinner. Until then, though, he is in a fight for his life, one he plans to win. Bartlett is a cancer patient and the first participant in a clinical trial at University Hospitals Seidman Cancer Center in Cleveland to test the safety of an immunotherapy drug — Pembrolizumab — when added to a regimen of surgery, chemotherapy and radiation therapy. Back to the beginning Bartlett went to the dentist in October for a checkup. "He had a sore in his mouth he thought was an abscess," explained his wife, Nancy Bartlett, who pointed out that, because radiation and chemo treatments cause the inside of the mouth to burn and blister, it is hard for Bartlett to talk. "When the dentist looked at his sore, he sent Richard to a specialist in Canton, and in early November, he had a biopsy done. It came back positive for cancer." From there, he was referred to Dr. Pierre Lavertu, director of head and neck surgery and oncology at University Hospitals, and Dr. Chad Zender from the otolaryngology department, who did Bartlett's surgery. "They let us know it was serious," said Nancy. "It had gone into the bone and the roof of the mouth, but they were not sure if it had gone into the lymph nodes. By the time we got through that appointment, [...]

Self-persuasion iPad app spurs low-income parents to protect teens against cancer-causing HPV

Source: https://medicalxpress.com/news/2017-03-self-persuasion-ipad-app-spurs-low-income.html Date: March 7, 2017 As health officials struggle to boost the number of teens vaccinated against the deadly human papillomavirus, a new study from Southern Methodist University, Dallas, found that self-persuasion works to bring parents on board. Currently public health efforts rely on educational messages and doctor recommendations to persuade parents to vaccinate their adolescents. Self-persuasion as a tool for HPV vaccinations has never been researched until now. The SMU study found that low-income parents will decide to have their teens vaccinated against the sexually transmitted cancer-causing virus if the parents persuade themselves of the protective benefits. The study's subjects—almost all moms—were taking their teens and pre-teens to a safety-net pediatric clinic for medical care. It's the first to look at changing parents' behavior through self-persuasion using English- and Spanish-language materials. "This approach is based on the premise that completing the vaccination series is less likely unless parents internalize the beliefs for themselves, as in 'I see the value, I see the importance, and because I want to help my child,'" said psychology professor Austin S. Baldwin, a principal investigator on the research. Depending on age, the HPV vaccine requires a series of two or three shots over eight months. External pressure might initially spark parents to action. But vaccinations decline sharply after the first dose. The new study follows an earlier SMU study that found guilt, social pressure or acting solely upon a doctor's recommendation was not related to parents' motivation to vaccinate their kids. The new [...]

2017-03-07T10:54:19-07:00March, 2017|Oral Cancer News|

Bill Snyder Addresses Health Situation

Source: http://www.kstatesports.com MANHATTAN, Kan. – Kansas State head football coach Bill Snyder addressed today reports of his current health, which will not affect his duties leading the Wildcat program. “I feel bad having to release this information about my health in this manner prior to sharing it in person with so many personal friends, distant family, players and their families, past and present, and many of the Kansas State football family so close to our program,” Snyder said. “But, with so much talk presently out there, I certainly owe it to everyone to make them aware of my condition. "I have been diagnosed with throat cancer and have been receiving outpatient treatment at the KU Medical Center for about three weeks and am getting along very well. The doctors and staffs at both KU Med and M.D. Anderson (in Houston, Texas) have been great; working so very well together to finalize the overall treatment plan which is being conducted in Kansas City. Both ‘teams’ have projected a positive outcome and have worked out a schedule that allows me to be in Kansas City for my regular treatments and still be back in the office on a regular basis through the first week of March. Sean, along with our coaching and support staffs, remain highly productive in carrying out their responsibilities keeping us on track. "I greatly appreciate our President, Richard Myers, and Athletic Director, John Currie, for their continued support, and I’m very grateful to those who have responded over [...]

2017-02-13T12:43:05-07:00February, 2017|Oral Cancer News|

Game changer’ HPV vaccine is now just 2 shots – not 3 – in bid to simplify

Source: www.dailymail.co.uk Author: Mary Kekatos for dailymail.com HPV vaccines will now be administered in two doses instead of three The virus is the most common sexually transmitted infection in the US But only 28% of boys and 42% of girls received the advised three doses in 2015 Doctors hope the new guidelines increase the number of kids who get the shot The HPV vaccine will now be administered in two doses instead of three, new guidelines declare. The new rules, published on Monday, come after years of campaigns from cancer experts insisting an easier schedule would encourage more people to protect themselves from the sexually-transmitted infection. Human papillomavirus (or, HPV) is the most common STI in the United States, affecting around 79 million people. It has been linked to numerous cancers - including prostate, throat, head and neck, rectum and cervical cancer. Experts claim more widespread vaccine coverage of middle school children could prevent 28,000 cancer diagnoses a year. Currently, fewer than half the children eligible for the vaccine - given out as three doses over six months - are covered. Experts blame the lengthy, arduous schedule. The American Cancer Society today endorsed the updated recommendations, which were released by the Advisory Committee on Immunization Practices (ACIP).  Dr Debbie Saslow, Senior Director, HPV Related and Women's Cancers for the American Cancer Society, said: 'In the past several years, studies have shown the vaccine is even more effective than expected. 'This new two-dose regimen is easier to follow, and we now [...]

2017-02-08T18:46:13-07:00February, 2017|Oral Cancer News|

We Have a Vaccine For Six Cancers; Why Are Less Than Half of Kids Getting It?

Author: Electra D. Paskett, Professor of Cancer Research, College of Medicine, The Ohio State University Source: http://theconversation.com Early in our careers, few of us imagined a vaccine could one day prevent cancer. Now there is a vaccine that keeps the risk of developing six Human Papillomavirus (HPV)-related cancers at bay, but adoption of it has been slow and surprising low. Although it’s been available for more than a decade, as of 2014 only 40 percent of girls had received the full three doses of the vaccine, while only 22 percent of boys had received all three. That is far lower than the 87 percent vaccination rates for the Tdap vaccine, which prevents tetanus, diptheria and acellular pertussis. Rates of uptake are low in all population groups. Some of the reasons include misinformation about the vaccine and why it’s administered to children. Because it is transmitted sexually in almost all cases, many parents assume their children do not need it until they are sexually active. Some believe that giving it will encourage early sexual behavior. Three separate doses on three separate doctor visits place a burden to many working parents. And, of course, there are those few who believe that vaccines are not good for children. Now, however, with the approval of a two-dose regimen for children under age 15, we have an opportunity to revisit the conversation with providers and parents and reinvigorate efforts to expand HPV vaccination. If successful, we may save tens of thousands of Americans from cancer [...]

2017-02-07T10:59:53-07:00February, 2017|Oral Cancer News|

Silk and stem cells are being used to generate salivary glands

Source: biotechin.asia Author: Manish Muhuri Saliva is a watery substance secreted by the salivary glands located in the mouth. Saliva is essential for good health, as it assists in speaking, swallowing, food digestion, preventing oral infections in addition to many other tasks. Without normal salivary function the frequency of dental caries, gum disease (gingivitis), and other oral problems increases significantly. Location and types of salivary glands in humans. Image Courtesy : Wikimedia Commons Dysfunction or reduction in activity of salivary glands can be caused by many factors, including diabetes, radiation therapy for head and neck tumors, aging, medication side effects, and Sjögren’s syndrome. Sjogren’s is an autoimmune disease where the body attacks its own tear ducts and salivary glands. Patients suffering from this disease have severely dry mouth. No treatments are currently available for dry mouth. Salivary glands, unfortunately, have very little regenerative capacity. The title must have left you wondering about the correlation between silk and saliva – what do they have in common? They are both actually part of a unique experiment going on in San Antonio, a study that could change the lives of millions of people who suffer from dry mouth. Chih-Ko Yeh , BDS, Ph.D., and Xiao-Dong Chen, MD, MS, Ph.D., of the UT Health San Antonio School of Dentistry decided there had to be a better way to help people than try to develop drugs and figured that stem cells may help solve a common, painful problem. Yeh said the idea is [...]

Padres Hall of Famer Randy Jones Battling Throat Cancer

Source: 10news.com Author: Mark Saunders Posted: Jan 26, 2017 SAN DIEGO - Legendary San Diego Padres pitcher Randy Jones is battling throat cancer, the team's website announced Thursday. Jones was reportedly diagnosed in November 2016 and has been undergoing radiation and chemotherapy treatments since December at Sharp's Hospital. "I feel positive," Jones said told the Padre's Bill Center. "They caught it early. It's all in the throat and not in the lymph nodes. I'm beating this thing." Jones said he used chewing tobacco as a player and has smoked cigars throughout his adult life. "I've completed 90 percent of my treatment," Jones told Center. He added that his physicians have said his cancer is linked to tobacco use. He also said his cancer is low-risk. Since his playing days he has remained heavily involved with the team. He is a spokesperson for the team and a local radio and television personality. The Friars drafted Jones in 1972, during the 5th round of the amateur draft. Jones pitched for the Padres from 1973-1980. He recorded a 3.42 ERA and 735 strikeouts through his career. He was the first Padre to win the National League Cy Young Award and the first Padre to start an All-Star Game. He was a National League all-star in 1975 and 1976, when he led the NL in ERA in 1975 and led in wins in 1976. Jones' number was retired by the team in 1997 and two years later, he was a member of the Padre's first Hall [...]

2017-01-26T13:50:37-07:00January, 2017|Oral Cancer News|
Go to Top